NFE2L2 and metabolic dysfunction-associated steatohepatitis: While there is still limited evidence in the literature that Nrf2 is activated in human subjects with NASH [67], Nrf2 deficiency has been repeatedly reported to favor the development of steatohepatitis and fibrosis in rodent models of NASH.